| Chronicles of EGFR tyrosine kinase inhibitors: targeting EGFR C797S containing triple mutations KB Duggirala, Y Lee, K Lee Biomolecules & Therapeutics 30 (1), 19, 2021 | 42 | 2021 |
| Allosteric Inhibitor TREA‐0236 Containing Non‐hydrolysable Quinazoline‐4‐one for EGFR T790M/C797S Mutants Inhibition S Lee, J Kim, KB Duggirala, A Go, I Shin, BC Cho, G Choi, CH Chae, ... Bulletin of the Korean Chemical Society 39 (7), 895-898, 2018 | 20 | 2018 |
| MA07. 08 JIN-A02, a highly effective 4th generation EGFR-TKI, targeting EGFR C797S triple mutation in NSCLC MR Yun, MR Yu, KB Duggirala, K Lee, A Jo, E Seah, C Kim, BC Cho Journal of Thoracic Oncology 17 (9), S69-S70, 2022 | 10 | 2022 |
| Novel allosteric glutaminase 1 inhibitors with macrocyclic structure activity relationship analysis EJ Lee, KB Duggirala, Y Lee, MR Yun, J Jang, R Cyriac, ME Jung, G Choi, ... Bioorganic & Medicinal Chemistry Letters 75, 128956, 2022 | 9 | 2022 |
| 999P JIN-A02, a fourth-generation, highly effective tyrosine kinase inhibitor with intracranial activity, targeting EGFR C797S mutations in NSCLC MR Yun, MR Yu, KB Duggirala, K Lee, SM Lim, A Jo, E Seah, C Kim, ... Annals of Oncology 33, S1010-S1011, 2022 | 6 | 2022 |
| N2, N4-diphenylpyrimidine-2, 4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of … K Lee, I Shin, G Choi, CH Chae, HJ Choe, ME Jung, BU Jeon, BC Cho, ... US Patent 11,253,516, 2022 | 2 | 2022 |
| Rational Design, Synthesis and Evaluation of Novel C6‐Bicycloalkaneimidazole Containing Imidazo[1,2‐b]pyridazines for ASK1 Inhibition Y Lee, J Jang, M Bibi, KB Duggirala, SH Ji, JH Lee, S Ahn, JS Song, ... Bulletin of the Korean Chemical Society 42 (6), 872-877, 2021 | 2 | 2021 |
| Identification of TRE‐130 as Reversible Inhibitor of Pan‐EGFR Mutants while Sparing EGFR Wild‐Type Activity KB Duggirala, H Choe, BU Jeon, ME Jung, A Go, B Lim, C Park, J Yoon, ... Bulletin of the Korean Chemical Society 40 (12), 1222-1225, 2019 | 2 | 2019 |
| JIN-A04, highly effective tyrosine kinase inhibitor targeting HER2 exon 20 insertion mutations in NSCLC MR Yu, MR Yun, JB Lee, JY Lee, SW Aum, SJ Choi, JY Park, SY Oh, ... Cancer Research 83 (7_Supplement), 4029-4029, 2023 | 1 | 2023 |
| Novel pyrimidine-2, 4-diamine derivatives, preparation method therefor, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer K Lee, KB Duggirala, G Choi, Y Lee, CH Chae, ME Jung, BC Cho US Patent App. 18/579,279, 2024 | | 2024 |
| Pyrimidine derivative, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient K Lee, KB Duggirala, GD Choi, CH Chae, ME Jung, Y Lee, BC Cho US Patent App. 18/294,422, 2024 | | 2024 |
| Abstract B076: Discovery of BBT-176 as fourth generation EGFR tyrosine kinase inhibitor KB Duggirala, K Lee Molecular Cancer Therapeutics 22 (12_Supplement), B076-B076, 2023 | | 2023 |
| P2. 09-11 JIN-A04, Highly Effective and Brain-penetrant Tyrosine Kinase Inhibitor Targeting HER2 Exon20 Insertion Mutations in NSCLC MR Yu, MR Yun, HB Cho, HB Choi, G Dong, SJ Choi, SY Oh, EJ Lee, ... Journal of Thoracic Oncology 18 (11), S335-S336, 2023 | | 2023 |
| Benzamide derivative, preparation method therefor, and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer K Lee, J Kim, BC Cho, G Choi, YUN Jiyeon, CW Park, KB Duggirala, ... US Patent App. 17/637,044, 2022 | | 2022 |
| N2, n4-diphenylpyrimidine-2, 4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of … K Lee, I Shin, G Choi, CH Chae, HJ Choe, ME Jung, BU Jeon, BC Cho, ... US Patent App. 17/675,917, 2022 | | 2022 |
